Published in Am J Cardiol on August 15, 2005
Costs of major intracranial, gastrointestinal and other bleeding events in patients with atrial fibrillation - a nationwide cohort study. BMC Health Serv Res (2017) 1.38
Genetic and environmental factors determining clinical outcomes and cost of warfarin therapy: a prospective study. Pharmacogenet Genomics (2009) 1.09
Bleeding complications during warfarin treatment in primary healthcare centres compared with anticoagulation clinics. Scand J Prim Health Care (2007) 1.00
Understanding the pharmacogenetic approach to warfarin dosing. Heart Fail Rev (2008) 0.94
D-dimer levels over time and the risk of recurrent venous thromboembolism: an update of the Vienna prediction model. J Am Heart Assoc (2014) 0.91
Predicting the risk of venous thromboembolism recurrence. Am J Hematol (2012) 0.88
Incidence, clinical impact and risk of bleeding during oral anticoagulation therapy. World J Cardiol (2011) 0.85
Implementing genotype-guided antithrombotic therapy. Future Cardiol (2010) 0.85
Stroke prevention with oral anticoagulation in older people with atrial fibrillation - a pragmatic approach. Aging Dis (2012) 0.82
Impact of regular physical activity on weekly warfarin dose requirement. J Thromb Thrombolysis (2016) 0.75
[Spontaneous hematoma of right angle of the transverse mesocolon: exceptional complication of anticoagulant therapy with vitamin K]. Pan Afr Med J (2016) 0.75
Exposure to non-therapeutic INR in a high risk cardiovascular patient: potential hazard reduction with genotype-guided warfarin (Coumadin) dosing. P R Health Sci J (2010) 0.75
Fibrinolysis for patients with intermediate-risk pulmonary embolism. N Engl J Med (2014) 9.33
Dabigatran versus warfarin in the treatment of acute venous thromboembolism. N Engl J Med (2009) 9.17
Venous thromboembolism risk and prophylaxis in the acute hospital care setting (ENDORSE study): a multinational cross-sectional study. Lancet (2008) 9.10
Long-term, low-intensity warfarin therapy for the prevention of recurrent venous thromboembolism. N Engl J Med (2003) 8.65
Electronic alerts to prevent venous thromboembolism among hospitalized patients. N Engl J Med (2005) 7.90
A pharmacogenetic versus a clinical algorithm for warfarin dosing. N Engl J Med (2013) 7.09
Extended use of dabigatran, warfarin, or placebo in venous thromboembolism. N Engl J Med (2013) 6.71
2014 ESC guidelines on the diagnosis and management of acute pulmonary embolism. Eur Heart J (2014) 6.32
Management of massive and submassive pulmonary embolism, iliofemoral deep vein thrombosis, and chronic thromboembolic pulmonary hypertension: a scientific statement from the American Heart Association. Circulation (2011) 5.16
Influence of androgen suppression therapy for prostate cancer on the frequency and timing of fatal myocardial infarctions. J Clin Oncol (2007) 5.12
Right heart thrombi in pulmonary embolism: results from the International Cooperative Pulmonary Embolism Registry. J Am Coll Cardiol (2003) 4.10
Randomized, placebo-controlled trial of dalteparin for the prevention of venous thromboembolism in acutely ill medical patients. Circulation (2004) 3.83
Treatment of acute venous thromboembolism with dabigatran or warfarin and pooled analysis. Circulation (2013) 3.73
Chronic thromboembolic pulmonary hypertension. N Engl J Med (2011) 3.37
Sildenafil improves exercise capacity and quality of life in patients with systolic heart failure and secondary pulmonary hypertension. Circulation (2007) 2.58
Modern surgical treatment of massive pulmonary embolism: results in 47 consecutive patients after rapid diagnosis and aggressive surgical approach. J Thorac Cardiovasc Surg (2005) 2.53
Effect of computerized clinical decision support on the use and yield of CT pulmonary angiography in the emergency department. Radiology (2011) 2.47
Cardiovascular outcomes in the Irbesartan Diabetic Nephropathy Trial of patients with type 2 diabetes and overt nephropathy. Ann Intern Med (2003) 2.47
Physical inactivity and idiopathic pulmonary embolism in women: prospective study. BMJ (2011) 2.34
Low-molecular-weight heparin and mortality in acutely ill medical patients. N Engl J Med (2011) 2.32
Massive pulmonary embolism. Circulation (2006) 2.27
Impact of achieved blood pressure on cardiovascular outcomes in the Irbesartan Diabetic Nephropathy Trial. J Am Soc Nephrol (2005) 2.25
The accuracy of the enzyme-linked immunosorbent assay D-dimer test in the diagnosis of pulmonary embolism: a meta-analysis. Ann Emerg Med (2002) 2.25
Right ventricular enlargement on chest computed tomography: prognostic role in acute pulmonary embolism. Circulation (2004) 2.21
The effect of excessive anticoagulation on mortality and morbidity in hospitalized patients with anticoagulant-related major hemorrhage. Arch Intern Med (2004) 2.11
Upper-extremity deep vein thrombosis. Circulation (2002) 2.09
Upper-extremity deep vein thrombosis: a prospective registry of 592 patients. Circulation (2004) 2.05
Right ventricular enlargement on chest computed tomography: a predictor of early death in acute pulmonary embolism. Circulation (2004) 1.97
Clinical validity of a negative computed tomography scan in patients with suspected pulmonary embolism: a systematic review. JAMA (2005) 1.82
Prognostic role of echocardiography among patients with acute pulmonary embolism and a systolic arterial pressure of 90 mm Hg or higher. Arch Intern Med (2005) 1.76
Normal D-dimer levels in emergency department patients suspected of acute pulmonary embolism. J Am Coll Cardiol (2002) 1.75
Effects of random allocation to vitamin E supplementation on the occurrence of venous thromboembolism: report from the Women's Health Study. Circulation (2007) 1.75
Cost effectiveness of thromboprophylaxis with a low-molecular-weight heparin versus unfractionated heparin in acutely ill medical inpatients. Am J Manag Care (2004) 1.69
Cardiac biomarkers for risk stratification of patients with acute pulmonary embolism. Circulation (2003) 1.68
Physician alerts to prevent symptomatic venous thromboembolism in hospitalized patients. Circulation (2009) 1.66
Efficacy and safety of fixed low-dose dalteparin in preventing venous thromboembolism among obese or elderly hospitalized patients: a subgroup analysis of the PREVENT trial. Arch Intern Med (2005) 1.64
Surgical pulmonary embolectomy: the resurrection of an almost discarded operation. Tex Heart Inst J (2013) 1.63
Percutaneous mechanical thrombectomy for acute pulmonary embolism: a double-edged sword. Chest (2007) 1.60
International normalized ratio increase before warfarin-associated hemorrhage: brief and subtle. Arch Intern Med (2004) 1.55
Assessing the prognosis of acute pulmonary embolism: tricks of the trade. Chest (2008) 1.54
Medication use evaluation: pharmacist rubric for performance improvement. Pharmacotherapy (2014) 1.52
Venous thromboembolism in patients with symptomatic atherosclerosis. Thromb Haemost (2011) 1.52
Cellular actors, Toll-like receptors, and local cytokine profile in acute coronary syndromes. Eur Heart J (2010) 1.51
Catheter-directed ultrasound-accelerated thrombolysis for the treatment of acute pulmonary embolism. Thromb Res (2011) 1.51
Thrombosis in suspected heparin-induced thrombocytopenia occurs more often with high antibody levels. Am J Med (2011) 1.48
Acute pulmonary embolectomy: a contemporary approach. Circulation (2002) 1.44
Thrombosis during pregnancy and the postpartum period. Am J Obstet Gynecol (2005) 1.42
Bleeding complications after systematic switch of routine thromboprophylaxis for major orthopaedic surgery. Thromb Haemost (2008) 1.41
Diagnosis of acute pulmonary embolism: always be vigilant. Am J Med (2007) 1.41
Cardiac decortication (epicardiectomy) for occult constrictive cardiac physiology after left extrapleural pneumonectomy. Chest (2002) 1.40
Improving clinical effectiveness in thromboprophylaxis for hospitalized medical patients. Am J Med (2009) 1.39
Randomized trial of physician alerts for thromboprophylaxis after discharge. Am J Med (2013) 1.39
Optimal duration of anticoagulation after venous thromboembolism: fixed and evidence-based, or flexible and personalized? Ann Intern Med (2009) 1.36
Predictors of major hemorrhage following fibrinolysis for acute pulmonary embolism. Am J Cardiol (2005) 1.34
Prognostic role of brain natriuretic peptide in acute pulmonary embolism. Circulation (2003) 1.32
Relationship between CT coronary angiography and stress perfusion imaging in patients with suspected ischemic heart disease assessed by integrated PET-CT imaging. J Nucl Cardiol (2007) 1.31
CT signs of right ventricular dysfunction: prognostic role in acute pulmonary embolism. JACC Cardiovasc Imaging (2011) 1.30
Multislice computed tomography for pulmonary embolism--a technological marvel. N Engl J Med (2005) 1.28
Fibrinolysis for acute pulmonary embolism. Vasc Med (2010) 1.27
Management of massive pulmonary embolism. Circulation (2005) 1.27
Routine pelvic and lower extremity CT venography in patients undergoing pulmonary CT angiography. AJR Am J Roentgenol (2008) 1.22
Venous thromboembolism risk and prophylaxis in hospitalised medically ill patients. The ENDORSE Global Survey. Thromb Haemost (2010) 1.21
International longitudinal registry of patients with atrial fibrillation at risk of stroke: Global Anticoagulant Registry in the FIELD (GARFIELD). Am Heart J (2011) 1.20
Clinical characteristics, management, and outcomes of patients diagnosed with acute pulmonary embolism in the emergency department: initial report of EMPEROR (Multicenter Emergency Medicine Pulmonary Embolism in the Real World Registry). J Am Coll Cardiol (2011) 1.19
Mortality rates and risk factors for asymptomatic deep vein thrombosis in medical patients. Thromb Haemost (2005) 1.19
Acute pulmonary embolism: part II: treatment and prophylaxis. Circulation (2006) 1.16
Prospective study of BMI and the risk of pulmonary embolism in women. Obesity (Silver Spring) (2009) 1.14
Time-resolved MR angiography: a primary screening examination of patients with suspected pulmonary embolism and contraindications to administration of iodinated contrast material. AJR Am J Roentgenol (2007) 1.14
Effect of low-dose aspirin on the occurrence of venous thromboembolism: a randomized trial. Ann Intern Med (2007) 1.14
Delays in diagnosis of deep vein thrombosis and pulmonary embolism. Chest (2005) 1.13
Warfarin dosing and cytochrome P450 2C9 polymorphisms. Thromb Haemost (2004) 1.12
Rationale and design of the Clarification of Optimal Anticoagulation through Genetics trial. Am Heart J (2013) 1.12
Spiral computed tomography for acute pulmonary embolism. Circulation (2004) 1.12
Venous thromboembolism in patients with active cancer. Thromb Haemost (2007) 1.09
Catheter-based reperfusion treatment of pulmonary embolism. Circulation (2011) 1.07
Adherence to pharmacological thromboprophylaxis orders in hospitalized patients. Am J Med (2010) 1.07
Pulmonary embolism: risk assessment and management. Eur Heart J (2012) 1.07
Medication errors associated with anticoagulant therapy in the hospital. Am J Cardiol (2004) 1.05
Tamoxifen: preventing breast cancer and placing the risk of deep vein thrombosis in perspective. Circulation (2005) 1.04
Triple rule-out CT in patients with suspicion of acute pulmonary embolism: findings and accuracy. Acad Radiol (2009) 1.04
Risk factors associated with symptomatic pulmonary embolism in a large cohort of deep vein thrombosis patients. Thromb Haemost (2005) 1.04
Venous thromboembolism in children. Circulation (2006) 1.04
Management of submassive pulmonary embolism. Circulation (2010) 1.03
Venous thromboembolism risk and prophylaxis in the acute care hospital setting (ENDORSE survey): findings in surgical patients. Ann Surg (2010) 1.02
The acutely decompensated right ventricle: pathways for diagnosis and management. Chest (2005) 1.02
Time trends in warfarin-associated hemorrhage. Am J Cardiol (2004) 1.02